在中枢神经系统参与的非小细胞肺癌中KRAS抑制:当前证据和未来方向
Oncology research and treatment
|February 16, 2026
概括
克拉斯G12C抑制剂对非小细胞肺癌 (NSCLC) 大脑转移有希望,但挑战仍然存在. 结合KRAS抑制剂与其他疗法的新策略正在探索中枢神经系统 (CNS) 参与患者改善结果.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 神经瘤学神经瘤学
背景情况:
- KRAS突变,特别是G12C,是非小细胞肺癌 (NSCLC) 的常见驱动因素.
- 大脑转移发生在高达40%的晚期KRAS突变NSCLC患者中,由于血脑屏障,这给治疗带来了重大挑战.
- 有限的临床数据存在,专门针对这些患者中枢神经系统 (CNS) 的参与.
研究的目的:
- 审查KRAS向治疗在中枢神经系统转移的NSCLC中不断变化的作用.
- 要突出最近关于KRAS G12C抑制剂的临床发现,如索托拉西布和阿达格拉西布.
- 讨论通过血脑屏障实现药物充分透的挑战.
主要方法:
- 关于KRAS G12C抑制剂的当前临床发现和文献的综述.
- 对向疗法的耐药性机制的分析.
- 探索新的组合策略.
主要成果:
- 阿达格拉西布显示有前途的内活动和中枢神经系统透.
- 关键的抵抗机制包括绕道信号,二次KRAS突变和SHP2反.
- 涉及SHP2抑制剂,免疫疗法和辐射的组合策略正在调查中.
结论:
- 尽管治疗进展,大脑转移仍然是KRAS突变NSCLC管理的一个重大挑战.
- 阿达格拉西布在NSCLC脑转移中显示出针对中枢神经系统的治疗潜力.
- 针对中枢神经系统特异性终点和综合治疗方法的进一步研究对于脑部受影响的患者至关重要.
相关概念视频
02:57Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
655
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
655